Disease-causing mutation in GPR54 reveals the importance of the second intracellular loop for class A G-protein-coupled receptor function.
The G-protein-coupled receptor (GPCR) GPR54 is essential for the development and maintenance of reproductive function in mammals. A point mutation (L148S) in the second intracellular loop (IL2) of GPR54 causes idiopathic hypogonadotropic hypogonadism, a disorder characterized by delayed puberty and infertility. Here, we characterize the molecular mechanism by which the L148S mutation causes disease and address the role of IL2 in Class A GPCR function. Biochemical, immunocytochemical, and pharmacological analysis demonstrates that the mutation does not affect the expression, ligand binding properties, or protein interaction network of GPR54. In contrast, diverse GPR54 functional responses are markedly inhibited by the L148S mutation. Importantly, the leucine residue at this position is highly conserved among class A GPCRs. Indeed, mutating the corresponding leucine of the alpha(1A)-AR recapitulates the effects observed with L148S GPR54, suggesting the critical importance of this hydrophobic IL2 residue for Class A GPCR functional coupling. Interestingly, co-immunoprecipitation studies indicate that L148S does not hinder the association of Galpha subunits with GPR54. However, fluorescence resonance energy transfer analysis strongly suggests that L148S impairs the ligand-induced catalytic activation of Galpha. Combining our data with a predictive Class A GPCR/Galpha model suggests that IL2 domains contain a conserved hydrophobic motif that, upon agonist stimulation, might stabilize the switch II region of Galpha. Such an interaction could promote opening of switch II of Galpha to facilitate GDP-GTP exchange and coupling to downstream signaling responses. Importantly, mutations that disrupt this key hydrophobic interface can manifest as human disease.
Wacker
Jennifer L
JL
Department of Pharmacology, University of Washington, Seattle, Washington 98195, USA.
Feller
David B
DB
Tang
Xiao-Bo
XB
Defino
Mia C
MC
Namkung
Yuree
Y
Lyssand
John S
JS
Mhyre
Andrew J
AJ
Tan
Xu
X
Jensen
Jill B
JB
Hague
Chris
C
D020816:Amino Acid Motifs / Q000235:genetics; D019943:Amino Acid Substitution; D002460:Cell Line; D044385:GTP-Binding Protein alpha Subunits / Q000235:genetics / Q000378:metabolism; D030342:Genetic Diseases, Inborn / Q000235:genetics / Q000378:metabolism*; D006153:Guanosine Diphosphate / Q000235:genetics / Q000378:metabolism; D006160:Guanosine Triphosphate / Q000235:genetics / Q000378:metabolism; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D007006:Hypogonadism / Q000235:genetics / Q000378:metabolism*; D017354:Point Mutation; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000378:metabolism*; D000074502:Receptors, Kisspeptin-1
D044385:GTP-Binding Protein alpha Subunits; C118688:KISS1R protein, human; D043562:Receptors, G-Protein-Coupled; D000074502:Receptors, Kisspeptin-1; D006153:Guanosine Diphosphate; D006160:Guanosine Triphosphate
Science. 1978 Nov 10;202(4368):631-3
100883
Annu Rev Pharmacol Toxicol. 2004;44:559-609
14744258
J Biol Chem. 1995 Sep 29;270(39):22820-6
7559413
J Biol Chem. 1993 Oct 25;268(30):22273-6
8226735
Biochem Biophys Res Commun. 1999 Oct 14;264(1):171-5
10527859
Endocrinology. 2004 Sep;145(9):4073-7
15217982
Science. 1997 Dec 12;278(5345):1907-16
9417641
Nat Clin Pract Endocrinol Metab. 2006 Jun;2(6):328-34
16932310
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10972-6
12944565
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4877-82
11320237
Pharmacol Rev. 2007 Sep;59(3):225-50
17878512
N Engl J Med. 2003 Oct 23;349(17):1614-27
14573733
Anal Biochem. 2005 Mar 1;338(1):136-42
15707944
Mol Pharmacol. 2007 Aug;72(2):219-30
17430994
Biochem Biophys Res Commun. 2003 Dec 26;312(4):1357-63
14652023
Biochemistry. 1987 May 19;26(10):2657-64
3038163
Eur J Endocrinol. 2004 Nov;151 Suppl 3:U83-8
15554891
Semin Reprod Med. 2007 Jul;25(4):272-86
17594608
J Clin Endocrinol Metab. 2001 Jun;86(6):2680-6
11397871
Nature. 1998 Jul 2;394(6688):35-8
9665125
PLoS Comput Biol. 2006 Feb;2(2):e13
16485037
Neuroendocrinology. 2004;80(4):264-72
15665556
Q Rev Biophys. 2006 May;39(2):117-66
16923326
Pharmacol Ther. 2006 Sep;111(3):949-73
16616374
Science. 2007 Nov 23;318(5854):1258-65
17962520
J Biol Chem. 1995 Jul 28;270(30):17741-8
7629074
Nat Rev Mol Cell Biol. 2008 Jan;9(1):60-71
18043707
Cell. 1997 Apr 18;89(2):251-61
9108480
Mol Pharmacol. 2007 Apr;71(4):959-64
17192495
Mol Pharmacol. 2006 Jan;69(1):397-405
16210429
J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15
16174713
Mol Cell Proteomics. 2007 May;6(5):835-44
17215244
Protein Sci. 2006 Jul;15(7):1679-90
16815918
J Biol Chem. 2006 Feb 3;281(5):2932-8
16319069
J Mol Biol. 2003 Aug 1;331(1):281-99
12875852
J Endocrinol. 2006 Jul;190(1):13-6
16837606
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):2001-6
17264214
Circ Res. 2002 Oct 18;91(8):672-80
12386143
Endocrinology. 2005 Jan;146(1):156-63
15375028
Science. 2005 Dec 9;310(5754):1686-90
16339447
Endocrinology. 2003 Jun;144(6):2220-8
12746278
Biochem Biophys Res Commun. 2005 Apr 8;329(2):684-92
15737640
J Biol Chem. 1998 Sep 18;273(38):24322-7
9733718
J Clin Endocrinol Metab. 2005 Mar;90(3):1849-55
15598687
J Biol Chem. 2008 Jul 4;283(27):18792-800
18468998